Pacira Pharmaceuticals (PCRX) Shares are Up 20.11%

Pacira Pharmaceuticals (PCRX) : Traders are bullish on Pacira Pharmaceuticals (PCRX) as it has outperformed the S&P 500 by a wide margin of 16.75% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 19.6%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 20.11% in the last 1 week, and is up 19.65% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Pacira Pharmaceuticals (NASDAQ:PCRX): The stock opened at $44.74 on Friday but the bulls could not build on the opening and the stock topped out at $44.74 for the day. The stock traded down to $42.31 during the day, due to lack of any buying support eventually closed down at $43.54 with a loss of -2.44% for the day. The stock had closed at $44.63 on the previous day. The total traded volume was 956,014 shares.

The stock has recorded a 20-day Moving Average of 16.66% and the 50-Day Moving Average is 9.66%. Pacira Pharmaceuticals, Inc. has dropped 8.07% during the last 3-month period . Year-to-Date the stock performance stands at -43.3%.

Pacira Pharmaceuticals (PCRX) : The most positive equity analysts on Pacira Pharmaceuticals (PCRX) expects the shares to touch $109, whereas, the least positive believes that the stock will trade at $47 in the short term. The company is covered by 8 Wall Street Brokerage Firms. The average price target for shares are $76.13 with an expected fluctuation of $17.68 from the mean.


Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.